Overview

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Status:
Completed
Trial end date:
2010-03-28
Target enrollment:
Participant gender:
Summary
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Aldesleukin
Interleukin-2